Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; 5 of the 62 sources its claims cite were checked for support.

Leptin is an effective treatment for hypothalamic amenorrhea

Open access

Abstract

Hypothalamic amenorrhea (HA) is associated with dysfunction of the hypothalamic-pituitary-peripheral endocrine axes, leading to infertility and bone loss, and usually is caused by chronic energy deficiency secondary to strenuous exercise and/or decreased food intake. Energy deficiency also leads to hypoleptinemia, which has been proposed, on the basis of observational studies as well as an open-label study, to mediate the neuroendocrine abnormalities associated with this condition. To prove definitively a causal role of leptin in the pathogenesis of HA, we performed a randomized, double-blinded, placebo-controlled trial of human recombinant leptin (metreleptin) in replacement doses over 36 wk in women with HA. We assessed its effects on reproductive outcomes, neuroendocrine function, and bone metabolism. Leptin replacement resulted in recovery of menstruation and corrected the abnormalities in the gonadal, thyroid, growth hormone, and adrenal axes. We also demonstrated changes in markers of bone metabolism suggestive of bone formation, but no changes in bone mineral density were detected over the short duration of this study. If these data are confirmed, metreleptin administration in replacement doses to normalize circulating leptin levels may prove to be a safe and effective therapy for women with HA.

Overview

CoChat Summary

## TL;DR

In this 36-week randomized, double-blind, placebo-controlled trial, metreleptin improved reproductive and neuroendocrine outcomes in women with hypothalamic amenorrhea (HA). The paper concludes that hypoleptinemia likely contributes to HA-related abnormalities and that physiologic leptin replacement may be an effective therapy.

## Key findings

  • Menstruation returned in 7 of 10 metreleptin-treated subjects versus 2 of 9 placebo-treated subjects (P = 0.0046); 4 of the menstruating metreleptin-treated subjects were ovulatory by midluteal progesterone (>10 ng/mL).
  • Metreleptin increased reproductive hormones: estradiol and progesterone were significantly higher than placebo (P = 0.0137 and P = 0.0342, respectively); the Discussion also states estradiol, progesterone, and fT3 increased while cortisol decreased.
  • Leptin replacement altered endocrine and bone markers: cortisol declined with metreleptin (P = 0.019 by treatment effect), IGF1:IGFBP-3 increased (P = 0.035), osteocalcin increased (P = 0.0019), and urinary NTX:creatinine increased less than in placebo (P = 0.0282 by treatment effect).
  • Body fat fell with metreleptin: mean loss of 2.02 kg of fat, with significant effects on total body fat mass (P = 0.023) and body fat percentage (P = 0.014); resting energy expenditure did not differ significantly (P = 0.78).

## Methods

  • Randomized, double-blinded, placebo-controlled trial of human recombinant leptin (metreleptin) over 36 weeks, with a week 52 follow-up after withdrawal.
  • Eligible participants were women aged 18–35 years with secondary hypothalamic amenorrhea for at least 6 months associated with strenuous exercise and/or low body weight; 20 participants were enrolled, with 11 assigned to metreleptin and 9 to placebo.
  • Main analyses used repeated-measures ANOVA for longitudinal outcomes; Fisher’s exact test was used for menstruation outcomes, and the paper reports last-observation-carried-forward analyses (with on-treatment analyses yielding similar results).

## Limitations

  • The paper states that 36 weeks was probably not long enough to detect changes in bone mineral density (BMD), and an open-label extension was planned to assess up to 2 years of treatment.
  • The paper states that measures of energy expenditure and food intake were limited: it measured resting rather than total energy expenditure, and 3-day food diaries may not have been sensitive enough.
  • The paper states an early withdrawal rate of 10% by week 20 and 35% by week 36; evident from the text, the study was small (20 participants), and some outcomes were based on fewer subjects because of withdrawals and missing serum for antibody testing (e.g., antileptin antibodies in 8 of 10 metreleptin-treated and 7 of 9 placebo-treated subjects).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1073/pnas.1015674108

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

4 Valid · 0 Not valid · 23 Not checked · 127 Own results and interpretations

62 more claims

Create a free account to see all 154 claims and to verify the 57 references still open.

See all claims — free account
  • Probably not a substantial claim. 56
  • It may state two separate claims as one. 45

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 48 references

Cited by

See all 287

Metadata

Authors
Chou, S. H., Chamberland, J. P., Liu, X., Matarese, G., Gao, C., Stefanakis, R., Brinkoetter, M. T., Gong, H., Arampatzi, K., & Mantzoros, C. S.
Affiliations
  • Beth Israel Deaconess Medical Center (US)
  • MultiMedica (IT)
Venue
Proceedings of the National Academy of Sciences
Published
2011-04-04
Volume
108
Issue
16
Pages
6585-6590
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W1966218936
Cited by
287
References
48
Citations by year
2026: 6 · 2025: 9 · 2024: 18 · 2023: 14 · 2022: 16 · 2021: 14 · 2020: 20 · 2019: 20 · 2018: 15 · 2017: 18 · 2016: 16 · 2015: 23 · 2014: 38 · 2013: 29 · 2012: 18
FWCI
34.54
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Amylin Pharmaceuticals
  • Harvard Catalyst (UL1-RR025758, RR025758, M01-RR-01032)
  • European Commission
  • National Institute on Aging (R01AG032030, AG032030.)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK079929, R01DK058785, R56DK058785, DK 79929, DK 58785, DK 81913, K24DK081913)
  • National Center for Research Resources (M01RR001032, UL1RR025758)
  • FP7 Ideas: European Research Council (202579)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
Keywords
hypothalamic amenorrhea, leptin, metreleptin, leptin replacement therapy, hypoleptinemia, energy deficiency, physical activity, infertility, bone metabolism, bone formation, bone mineral density, neuroendocrine function, menstrual recovery
MeSH terms
Adolescent, Adult, Amenorrhea, Feeding and Eating Disorders, Eating, Female, Humans, Hypothalamic Diseases, Hypothalamo-Hypophyseal System, Pituitary-Adrenal System, Time Factors, Leptin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Leptin is an effective treatment for hypothalamic amenorrhea. https://app.cochat.ai/papers/10.1073/pnas.1015674108
The paper
Chou, S. H., Chamberland, J. P., Liu, X., Matarese, G., Gao, C., Stefanakis, R., Brinkoetter, M. T., Gong, H., Arampatzi, K., & Mantzoros, C. S. (2011). Leptin is an effective treatment for hypothalamic amenorrhea. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1015674108

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.